Q3 2016 Earnings Estimate for Ascendis Pharma A/S Issued By Wedbush (ASND)
Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Wedbush lowered their Q3 2016 EPS estimates for shares of Ascendis Pharma A/S in a report released on Tuesday. Wedbush analyst L. Moussatos now expects that the brokerage will post earnings per share of ($0.71) for the quarter, down from their prior forecast of ($0.66). Wedbush currently has a “Outperform” rating and a $34.00 price target on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2016 earnings at ($0.71) EPS, FY2016 earnings at ($3.10) EPS, FY2017 earnings at ($2.87) EPS, FY2018 earnings at ($3.33) EPS, FY2019 earnings at ($4.15) EPS and FY2020 earnings at ($2.93) EPS.
ASND has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Tuesday. Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd. Finally, TheStreet upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at 20.02 on Thursday. The firm has a 50-day moving average price of $19.46 and a 200-day moving average price of $16.20. Ascendis Pharma A/S has a 52 week low of $11.92 and a 52 week high of $21.70. The stock’s market cap is $504.36 million.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative return on equity of 47.61% and a negative net margin of 818.32%.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.